Ballard, CG, Gauthier, S, Cummings, JL, Brodaty, H, Grossberg, GT, Robert, P et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurosci
2009; 5: 245–55.
Alzheimer's Society. Optimising Treatment and Care for Behavioural and Psychological Symptoms of Dementia.
Alzheimer's Society, 2013.
Ballard, C, Howard, R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci
2006; 7: 492–500.
Ballard, C, Lana, M, Theodoulou, M, Douglas, S, McShane, R, Jacoby, R, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med
2008; 5: 76.
Devanand, DP, Mintzer, J, Schultz, SK, Andrews, HF, Sultzer, DL, de la Pena, D, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med
2012; 367: 1497–507.
Schneider, LS, Dagerman, KS, Insel, P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA
2005; 294: 1934–43.
Banerjee, S. The Use of Antipsychotic Medication for People with Dementia: Time for Action.
Department of Health, 2009.
Health and Social Care Information Centre. National Dementia & Antipsychotic Prescribing Audit 2012.
Gerhard, T, Huybrechts, K, Olfson, M, Schneeweiss, S, Bobo, WV, Doraiswamy, PM, et al. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry
2014; 205: 44–51.
Kales, HC, Kim, HM, Zivin, K, Valenstein, M, Seyfried, LS, Chiang, C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry
2012; 169: 71–9.